Amylyx Pharmaceuticals financials
$29.28−1.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $87.4M | $380.8M | $22.2M |
| Gross profit | $0.00 | $81.4M | $355.3M | $19.2M |
| Gross margin | — | 93.2% | 93.3% | 86.5% |
| Operating income | -$153.3M | -$314.7M | $38.8M | -$201.3M |
| Net income | -$144.7M | -$301.7M | $49.3M | -$198.4M |
| Net margin | — | −345.4% | 12.9% | −892.4% |
| Diluted EPS | $-1.53 | $-4.43 | $0.70 | $-3.39 |
| EBITDA | -$152.8M | -$172.3M | $39.9M | -$200.9M |
| Operating cash flow | -$123.3M | -$167.6M | $11.9M | -$179.9M |
| Free cash flow | -$123.5M | -$167.8M | $10.7M | -$182.4M |
| Diluted shares | 94.6M | 68.1M | 70.0M | 58.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $226.7M | $77.4M | $170.2M | $62.5M |
| Short-term investments | $90.3M | $99.1M | $201.2M | $284.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $332.6M | $193.6M | $517.5M | $391.5M |
| Total liabilities | $27.4M | $28.9M | $84.0M | $50.8M |
| Shareholders' equity | $305.3M | $164.8M | $433.4M | $340.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology